HLIT241220P30000
- 14.20
- 0.000.00%
Harmonic Newsroom
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Collegium Pharmaceutical (COLL)
Stifel Maintains Harmonic(HLIT.US) With Buy Rating, Maintains Target Price $23
TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)
Harmonic Is Maintained at Outperform by Northland Capital Markets
Rosenblatt Securities Maintains Harmonic(HLIT.US) With Buy Rating, Cuts Target Price to $16
Raymond James Downgrades Harmonic to Outperform From Strong Buy, Price Target Is $14
Needham Maintains Harmonic(HLIT.US) With Buy Rating, Maintains Target Price $18
Harmonic Price Target Maintained With a $18.00/Share by Needham
Harmonic Analyst Ratings
Barclays Maintains Harmonic(HLIT.US) With Buy Rating, Cuts Target Price to $17
Harmonic Analyst Ratings
Rosenblatt Maintains Buy on Harmonic, Maintains $18 Price Target
Harmonic Drive Systems (HSYDF) Was Downgraded to a Sell Rating at Jefferies
Hold Rating on Harmonic Drive Systems Amidst Sales Decline and Uncertain Recovery
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Third Harmonic Bio Analyst Ratings
Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Harmonic Price Target Raised to $20.00/Share From $14.00 by Barclays